Cas:71278-17-6 Phytyl heneicosanoate manufacturer & supplier

We serve Chemical Name:Phytyl heneicosanoate CAS:71278-17-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

Phytyl heneicosanoate

Chemical Name:Phytyl heneicosanoate
CAS.NO:71278-17-6
Synonyms:Phytyl heneicosanoate
Molecular Formula:C41H80O2
Molecular Weight:604
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:
Exact Mass:
LogP:

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like Phytyl heneicosanoate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Phytyl heneicosanoate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Phytyl heneicosanoate Use and application,Phytyl heneicosanoate technical grade,usp/ep/jp grade.


Related News: Lonza is investing CHF 20 million in GMP laboratories and mid-scale manufacturing assets at its API manufacturing center in Nansha, China. The investment will allow Lonza to provide a smoother transition from small-scale to large-scale manufacturing for customers. (4-bromo-2-fluorophenyl)-[4-(2,5-dihydropyrrol-1-ylmethyl)phenyl]methanone manufacturers The company forecasts that the 70-strong team will grow by around 50% in the next three years to support its clinical and commercial API manufacturing capabilities. 8-(3,5-DIFLUOROPHENYL)-8-OXOOCTANOIC ACID suppliers “The Agency also noted that no effect was seen in the two studies that included patients from EU populations, including the most recent study which involved patients who were receiving the maximum and optimal treatment for their Parkinson’s disease,” EMA said. ethyl 2-(4-iodobenzoyl)benzoate vendor & factory “The Agency also noted that no effect was seen in the two studies that included patients from EU populations, including the most recent study which involved patients who were receiving the maximum and optimal treatment for their Parkinson’s disease,” EMA said.,The use of the Spikevax vaccine in children from 12 to 17 years of age will be the same as in people aged 18 and above, EMA said.